Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2
Pfizer's Phase 2 study of tilrekimig (PF-07275315) in moderate-to-severe atopic dermatitis met its primary endpoint, showing significant skin clearance at Week 16. The study reported EASI-75 rates of 62.5% for 450 mg Q2W and 58.5%-61.0% for 200-400 mg Q4W doses, compared to 19.9%-9.1% for placebo. Tilrekimig was well-tolerated, with no dose-dependent safety signals. Pfizer has initiated Phase 3 trials for tilrekimig in atopic dermatitis, asthma, and COPD.
How this was made
The 30-second read
Why it matters
The data could accelerate Pfizer's immunology pipeline valuation and affect related biotech stocks.
Market read
First‑time disclosure of significant Phase 2 efficacy may drive short‑term stock movement and longer‑term valuation shifts.
What to watch
Regulatory timelines and competition from existing IL‑4/IL‑13 blockers may limit upside.
Background
Pfizer's tilrekimig is a trispecific antibody targeting IL‑4, IL‑13 and TSLP, presented at the EADV Congress.
Ticker impact
Pfizer presented new Phase 2 data showing significant skin clearance for tilrekimig in atopic dermatitis.
likely upside as investors price in potential future approvals.
Statistically significant efficacy and tolerability data for a first‑in‑class trispecific antibody can boost expectations for Phase 3 and future sales.
Market effects
Strengthens the biotech/dermatology pipeline outlook and may lift peer stocks in the atopic dermatitis space.
U.S. biotech sector could see modest gains.
Potentially influences global investors tracking innovative immunology therapeutics.
Counterpoint
If Phase 3 fails to meet expectations, the current hype could reverse sharply.
Key entities
- CompanyPfizer Inc.
Developer of tilrekimig.
- ExecutiveMichael Vincent
Chief Inflammation & Immunology Officer at Pfizer.
